Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_2
3
60%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

completed360%
unknown120%
withdrawn120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

NCT04885855
withdrawn

Hepatitis C Treatment Study in Myanmar

NCT03158857
completedphase_2

A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study

NCT03236506
unknown

Hepatitis c and Vitamin D and Iron Status

NCT03166280
completedphase_2

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

NCT02349048

Clinical Trials (5)

Showing 5 of 5 trials
NCT04885855Phase 2

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Completed
NCT03158857

Hepatitis C Treatment Study in Myanmar

Withdrawn
NCT03236506Phase 2

A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study

Completed
NCT03166280

Hepatitis c and Vitamin D and Iron Status

Unknown
NCT02349048Phase 2

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5